Trial reportWorld journal of urology2026
Intermediate-term oncological and functional outcomes of neoadjuvant 177-Lu-PSMA-I&T radionuclide treatment followed by radical prostatectomy.
Trial report in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the intermediate-term oncological and functional outcomes in patients with high-risk prostate cancer (HRPCa) who were treated with neoadjuvant lutetium-177-prostate-specific membrane antigen (LuPSMA) followed by robotic-assisted laparoscopic radical prostatectomy (RARP).
methodsAn open-label, single-arm clinical trial enrolled patients with HRPCa and increased uptake on PSMA-PET/CT. Two or three LuPSMA doses (7.4 GBq) were given followed by RARP with lymph node dissection. Oncological outcomes (histological and radiological findings, biochemical recurrence-free survival [bRFS]), changes in urinary and sexual functions and quality of life were analyzed.
resultsThirteen patients (median age 67) were included. Over a median follow-up of 58 months (IQR 52, 63), bRFS rate was 42% with a median of 12 months (IQR 12, 30) from surgery to biochemical recurrence (BCR). BCR occurred in all three patients with significant positive surgical margins (sPSM) compared to 4/9 patients (44%) without sPSM. Log-rank analysis revealed a statistically significant difference in bRFS between these two groups (p = 0.009). In the subgroup of patients with BCR, the adverse effects of salvage radiation and androgen deprivation therapy after LuPSMA and subsequent RARP did not appear to be exacerbated by prior administration of LuPSMA. The preliminary nature of this trial, combined with the small cohort, requires that the oncological findings be interpreted with caution.
conclusionsFollow-up for more than four years showed that treatment with neoadjuvant LuPSMA followed by RARP appears to be safe for patients with HRPCa. However, more than half of these patients experienced BCR and required salvage therapy.
Indexed as
Identifiers
41931162What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.